Genomic Health kept at market outperform by JMP

JMP Securities analyst Charles Duncan reiterated Genomic Health Inc. at market outperform and a $16 price target. The Food and Drug Administration notified the company by letter that it will discuss Oncotype DX for breast cancer with Genomic Health. JMP noted the letter indicates the FDA's willingness to work with Genomic to determine "the least burdensome ways that Genomic Health may fulfill any premarket requirements of the Oncotype DX test that may apply." Shares of the Redwood City, Calif., biotechnology company were down $1.49, or 9.61%, at $14.01 on volume of 340,104 shares versus the three-month running average of 123,971 shares. (Nasdaq: GHDX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.